⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16837745 | 0.90 | GAA (0.33) | — | |
| SCHEMBL21409043 | 0.74 | — | — | |
| SCHEMBL13928657 | 0.68 | ALDH1A1 (0.36) | — | |
| SCHEMBL15868363 | 0.68 | — | — | |
| SCHEMBL7506778 | 0.68 | GAA (0.32) | — | |
| 2-(Nitromethylene)Imidazolidine SCHEMBL2069003 | 0.63 | — | — | |
| SCHEMBL28787415 | 0.62 | — | — | |
| SCHEMBL31372632 | 0.60 | — | — | |
| SCHEMBL10734147 | 0.60 | CHRNA1 (0.33) | — | |
| SCHEMBL7514475 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4709708-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2026-03-18 | — | — | EP | disclosed |
| EP-4045498-B1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | UNIV CALIFORNIA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2024233603-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ICAGEN, LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| CN-118515634-A | Preparation method of oxetane for nano-coating based on catalytic reaction | 深圳蓝海源科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-12054494-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2024-08-06 | — | — | US | disclosed |
| EP-3778573-B1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| EP-2297102-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |